ArticleSchizophrenia (Heidelberg, Germany)2025
An exploratory network analysis to investigate schizotypy's structure using the 'Multidimensional Schizotypy Scale' and 'Oxford-Liverpool Inventory' in a healthy cohort.
Article in Schizophrenia (Heidelberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Uncertainty modeling in multimodal speech analysis across the psychosis spectrum.NPJ digital medicine · 2026Article
- Mapping Schizotypy and Subthreshold Psychotic Experiences in a Resilience-Risk Network: Insights from a Population-Based Study.Schizophrenia bulletin open · 2026Article
- The unique contribution of Schizotypal personality subscales to psychotic-like experiences and social-personality factors in Hong Kong community youths.Frontiers in psychiatry · 2026Article
- Altered white matter microstructure of language pathways and semantic cognition deficiencies in early psychosis.Schizophrenia (Heidelberg, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Schizophrenia spectrum disorders and schizotypy share traits across positive, negative, and disorganised domains. Instruments like the Multidimensional Schizotypy Scale (MSS) and the Oxford-Liverpool Inventory (O-LIFE) offer nuanced perspectives on schizotypy, including its expression as a personality trait and its potential clinical outcomes. This study investigates the structure of schizotypy using exploratory graph analysis (EGA) to analyse how the MSS and O-LIFE operationalise the construct in the same sample of German speakers. This approach allows comparison of their factorial structures from both statistical and clinical perspectives, while also assessing cross-cultural validity. 1059 German-speaking, healthy participants completed the MSS and O-LIFE questionnaires. EGA was conducted to identify dimensional structures within each scale, utilising the graphical lasso algorithm for network estimation and the Walktrap community detection method for clustering. Confirmatory factor analysis was used to assess model fit and reliability, using indices such as the comparative fit index and root mean square error of approximation. EGA of the MSS revealed three primary dimensions and an additional 'dissociated' domain. This four-dimensional model showed improved fit and reliability compared to the original model. For the O-LIFE, EGA identified a refined four-factor structure comprising: 'cognitive and behavioural disorganisation,' 'introversion', 'unusual experiences', and 'environmental valence', all validated by confirmatory analyses. This study supports the multidimensional view of schizotypy, introducing new factor structures in the MSS and O-LIFE that emphasise the previously unexplored domains 'dissociated' and 'environmental valence.' These findings highlight the value of culturally adaptive tools in enhancing schizotypy assessment and intervention strategies.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.